TB-500 vs Teduglutide
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
TB-500 is a synthetic peptide that copies the active region of thymosin beta-4, a natural protein that controls how cells build and move their internal skeleton. Most TB-500 products reproduce the short LKKTETQ sequence (residues 17 to 23) responsible for binding actin and driving cell migration, which is why it gets marketed for tendon, muscle, and wound repair. Here is the honest part: there are essentially no completed human trials of the TB-500 fragment itself, and almost all the human clinical data is for the full-length thymosin beta-4 molecule, which is related but not the same thing.
Also: Gattex, Revestive
Teduglutide is a 33-amino-acid GLP-2 analog approved for short bowel syndrome (SBS) in people who depend on IV nutrition or fluids. GLP-2 is the gut's own growth signal, and teduglutide makes the remaining intestine grow taller villi and absorb more, so some patients can cut back the hours they spend hooked to a drip. The FDA approved it as Gattex in December 2012 (children 1 year and older were added in 2019), and in Europe it is sold as Revestive. It works, but it is a serious daily injection with real monitoring requirements, not a gut-health supplement.
Key Comparison Insights
- Teduglutide is FDA approved, while TB-500 remains in research stages.
- Both peptides belong to the Healing category, suggesting similar primary applications.
- Teduglutide has stronger research evidence (FDA Approved) compared to TB-500 (Animal Studies).
Detailed Comparison
| Attribute | TB-500 | Teduglutide |
|---|---|---|
| Category | Healing | Healing |
| FDA Status | Not FDA Approved | FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Thymosin beta-4 works by grabbing onto G-actin, the building-block form of actin, and acting as the main reservoir cells use to remodel their cytoskeleton. That control over actin lets cells migrate into wounds, which is the proposed basis for faster tissue repair. The active heptapeptide sequence LKKTETQ is the piece that does the actin binding, and TB-500 is built around it. Beyond cell movement, thymosin beta-4 has shown anti-inflammatory effects and pro-angiogenic activity in lab models. Keep in mind that injecting a short synthetic fragment is not guaranteed to reproduce everything the full protein does, so the mechanism story is borrowed largely from research on the parent molecule. | Teduglutide differs from natural GLP-2 by one amino acid (glycine swapped in at position 2), which shields it from DPP-4 breakdown and stretches its half-life from minutes to roughly 2 hours in healthy people (1.3 hours in SBS). It binds GLP-2 receptors on cells in the intestinal wall, which release local growth factors that increase villus height and crypt depth, improve blood flow to the gut, and slow gastric emptying and secretions. Net result: more absorptive surface and more time to absorb. The same growth signal is the reason for its main safety concern, because it can also speed the growth of polyps or existing tumors in the gut, so the label requires colonoscopy before and during treatment. |
| Common Dosing | 2-2.5 mg twice weekly (loading), then 2.5 mg once weekly (maintenance) 2x weekly for 4-6 weeks, then 1x weekly | 0.05 mg/kg once daily (labeled dose) Once daily |
| Administration | Subcutaneous or intramuscular injection | Subcutaneous injection, rotating between abdominal quadrants, thighs, or arms |
| Typical Duration | 4-6 weeks loading, then maintenance | Long-term, with assessment of benefit and ongoing monitoring; IV support is weaned as absorption improves |
| Best Time to Take | Morning or evening | Same time each day, any time of day |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The strongest evidence is preclinical and is mostly about full-length thymosin beta-4, not the TB-500 fragment. Animal studies consistently show accelerated wound healing, reduced scarring, and improved recovery in tendon, skin, and cardiac injury models. On the human side, the biotech company RegeneRx ran the molecule (as RGN-259 eye drops and RGN-352 injection) through actual clinical trials: a placebo-controlled Phase 3 study of RGN-259 in neurotrophic keratopathy reported corneal healing in 6 of 10 treated patients versus 1 of 8 on placebo, and an injectable cardiac program reached Phase 2 before a manufacturing hold. But those programs used full-length thymosin beta-4, not the 7-amino-acid TB-500 fragment sold for research. For the fragment specifically, there are no completed, published human efficacy trials for muscle or tendon repair, and a recently listed cardiovascular biomarker study is early-stage. So: real animal data, real human data for the parent protein, and a near-total gap for TB-500 as sold. | In the pivotal adult trial (Study 1, NCT00798967), 86 adults with SBS were randomized to teduglutide 0.05 mg/kg daily or placebo for 24 weeks. 63% on teduglutide versus 30% on placebo were responders (at least a 20% cut in weekly IV support at weeks 20 and 24), and weekly IV volume fell 4.4 L versus 2.3 L. In the 2-year open-label extension, 93% of the 30 patients who completed 30 months reached at least a 20% reduction, and a minority came off IV support entirely. An earlier trial (Study 3) used a different primary endpoint that missed at the higher dose, though responder rates at 0.05 mg/kg were 46% versus 6%. A 24-week pediatric study of 59 children aged 1 to 17 led to the 2019 approval: 69% on 0.05 mg/kg cut IV support by at least 20%, and 3 of 26 weaned off. Honest caveats: it is a lifelong therapy for most, benefits fade if stopped, and colon-in-continuity patients often respond less dramatically than those with a stoma. Longer-acting GLP-2 drugs (glepaglutide, apraglutide) are trying to replace the daily shot. |
Frequently Asked Questions: TB-500 vs Teduglutide
What is the difference between TB-500 and Teduglutide?
TB-500 is a healing peptide that tb-500 is a synthetic peptide that copies the active region of thymosin beta-4, a natural protein that controls how cells build and move their internal skeleton. most tb-500 products reproduce the short lkktetq sequence (residues 17 to 23) responsible for binding actin and driving cell migration, which is why it gets marketed for tendon, muscle, and wound repair. here is the honest part: there are essentially no completed human trials of the tb-500 fragment itself, and almost all the human clinical data is for the full-length thymosin beta-4 molecule, which is related but not the same thing. Teduglutide is a healing peptide that teduglutide is a 33-amino-acid glp-2 analog approved for short bowel syndrome (sbs) in people who depend on iv nutrition or fluids. glp-2 is the gut's own growth signal, and teduglutide makes the remaining intestine grow taller villi and absorb more, so some patients can cut back the hours they spend hooked to a drip. the fda approved it as gattex in december 2012 (children 1 year and older were added in 2019), and in europe it is sold as revestive. it works, but it is a serious daily injection with real monitoring requirements, not a gut-health supplement. The main differences lie in their mechanisms of action and clinical applications.
Which is better, TB-500 or Teduglutide?
Neither is universally "better" - the choice depends on your specific goals. TB-500 is typically used for healing purposes, while Teduglutide is used for healing. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can TB-500 and Teduglutide be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using TB-500 and Teduglutide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.